Although kinase inhibitors are becoming first- or second-line therapies for many cancers, issues with toxicity and serious adverse events remain. Xcovery Inc. believes its medicinal chemistry approach can generate kinase inhibitors with lower toxicity and larger therapeutic windows than existing compounds.

The company hopes to have up to three molecules in the clinic by the end of next year.